TABLE 4.
Associations between polymorphisms in MTHFR (A1298C, C677T), MTRR (A66G), and MTR (A2756G) and the risk of BE and esophageal cancers in SDH and ACS participants
| SDH | ACS | |||||
| SNP | Genotype | Frequency in ACS controls | BE without dysplasia, 510 Controls, 236 cases | BE with dysplasia, 510 Controls, 91 cases | EAC 1303 Controls, 501 cases | ESCC 1303 Controls, 177 cases |
| % | OR (95%CI)2 | |||||
| MTHFR A1298C, rs1801131 | AA | (46.8) | 1.0 (ref) | 1.0 (ref) | 1.0 (ref) | 1.0 (ref) |
| AC | (43.9) | 1.33 (0.91–1.94) | 1.45 (0.84–2.50) | 1.19 (0.93–1.52) | 0.98 (0.68–1.43) | |
| CC | (9.3) | 0.82 (0.40–1.69) | 0.51 (0.15–1.77) | 1.22 (0.80–1.84) | 1.79 (1.03–3.13) | |
| P-value1 | 0.22 | 0.16 | 0.35 | 0.07 | ||
| MTHFR C677T, rs1801133 | CC | (45.6) | 1.0 (ref) | 1.0 (ref) | 1.0 (ref) | 1.0 (ref) |
| CT | (42.6) | 1.15 (0.77–1.70) | 1.90 (1.08–3.36) | 1.06 (0.83–1.35) | 0.85 (0.58–1.23) | |
| TT | (11.8) | 0.94 (0.52–1.71) | 0.28 (0.08–0.97) | 0.70 (0.47–1.05) | 0.96 (0.56–1.66) | |
| P-value1 | 0.72 | 0.003 | 0.61 | 0.61 | ||
| MTRR A66G, rs1801394 | GG | (31.2) | 1.0 (ref) | 1.0 (ref) | 1.0 (ref) | 1.0 (ref) |
| GA | (50.7) | 1.10 (0.71–1.69) | 0.61 (0.32–1.14) | 0.93 (0.72–1.20) | 0.94 (0.63–1.40) | |
| AA | (18.1) | 1.16 (0.68–1.98) | 1.28 (0.64–2.57) | 0.96 (0.69–1.35) | 1.46 (0.90–2.37) | |
| P-value1 | 0.84 | 0.17 | 0.84 | 0.13 | ||
| MTR A2756G, rs1805087 | AA | (63.9) | 1.0 (ref) | 1.0 (ref) | 1.0 (ref) | 1.0 (ref) |
| AG | (32.7) | 0.84 (0.56–1.26) | 1.42 (0.82–2.45) | 0.89 (0.69–1.15) | 1.08 (0.74–1.57) | |
| GG | (3.4) | 1.81 (0.74–4.40) | 1.57 (0.30–8.31) | 1.28 (0.68–2.39) | 1.02 (0.41–2.97) | |
| P-value1 | 0.24 | 0.43 | 0.48 | 0.91 | ||
1
Type 3 analysis of effect, Wald chi-square.
2
Multivariable adjustment for age, gender, education, BMI 1 y previously, frequency of heartburn or acid reflux 10 y prior to diagnosis, lifetime alcohol intake, pack-years of smoking, NSAID use, and total energy intake.